Status:
COMPLETED
Safety Study for Beta Thalassemia Subjects on PTG-300
Lead Sponsor:
Protagonist Therapeutics, Inc.
Conditions:
β-thalassemia
Ineffective Erythropoiesis
Eligibility:
All Genders
12-65 years
Phase:
PHASE2
Brief Summary
In this study will investigate long term safety and use of the PTG-300 in Beta Thalassemia patients.
Detailed Description
The PTG-300-03 study will study beta thalassemia patients on PTG-300 for two years. The dose and dose frequency for each subject enrolling in the PTG-300-03 study will be based on the last dose and fr...
Eligibility Criteria
Inclusion
- NTD and TD β-thalassemia subjects who completed Week 12 and Week 16 respectively in Study PTG-300-02.
Exclusion
- Subjects who discontinued prematurely from study 300-02 (before Week 12 in NTD and Week 16 in TD).
Key Trial Info
Start Date :
May 10 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2020
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT04054921
Start Date
May 10 2019
End Date
July 31 2020
Last Update
July 16 2021
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
UCSF Benioff Children's Hospital
Oakland, California, United States, 94609
2
Boston Children's Hospital
Boston, Massachusetts, United States, 02215
3
Laiko General Hospital of Athens
Athens, Greece, 11526
4
Athens General Hospital 'G Gennimatas'
Athens, Greece, 11527